Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression - Test2 - elhamkhani - TriplyDB

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

http://www.wikidata.org/entity/Q30501271

about

Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies The outdoor air pollution and brain health workshop Multiple system atrophy: a clinical and neuropathological perspective Glia and alpha-synuclein in neurodegeneration: A complex interaction Biochemical premotor biomarkers for Parkinson's disease Emerging candidate biomarkers for Parkinson's disease: a review Predicting cognitive decline in Parkinson's disease: can we ask the genes?CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease.Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease.Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia Metabolomic biomarkers as strong correlates of Parkinson disease progression Phosphorylated α-synuclein in Parkinson's disease.Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.Targeted discovery and validation of plasma biomarkers of Parkinson's disease.Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease The role of biomarkers and imaging in Parkinson's disease.Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels.Towards translational therapies for multiple system atrophy Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease Analysis of extracellular RNA in cerebrospinal fluid Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy.Atypical parkinsonism: an update.Different patterns of cytokines and chemokines combined with IFN-γ production reflect Mycobacterium tuberculosis infection and disease.Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease.Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathies Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity

P2860

Q26744782-B63491F9-626E-4F38-8DF8-53D2B7082F5E Q26785974-7767FE8C-6E10-469B-ACD4-D556EA1DE6BD Q26795984-FCEF164F-1599-40E1-833F-A1A67D840257 Q26823021-53CE32F3-9AC4-4432-84D5-97503BA2FD3F Q26829838-DD38079C-A4BE-4493-91C8-94BCA6AA7688 Q26851153-EC82052D-4279-4FF7-BD9E-E7555FA1E72D Q27008467-8DC1F4FE-3911-4563-94CA-C9AC45328D5E Q27015018-97106D19-2E4D-4256-A4F3-F586B6058C81 Q27025463-ED0750BF-0CDC-440D-AB21-54A5B00BCD35 Q27304608-919F625D-9A48-42F8-AD16-AECECE2DA45E Q27311994-56468691-9E21-4449-AB1E-F2DF3337AECA Q27314618-95C9F3F7-73C9-4480-93D5-418705E48253 Q27322563-882A1986-CB08-47B1-970D-BE537984F52C Q27333599-E21C11DA-0C76-4391-AF0A-00EC9D73AA29 Q27686837-22EC9C95-0752-432C-9A99-07556A869D11 Q28072061-6E14BB54-F9ED-43DE-85D4-8A520CBAB076 Q28076121-DBEC29FF-5730-4DE4-8477-66AC11EF04DC Q28082380-1E00AF56-0B8E-4CA9-A0FF-5EFFC19A714C Q28083203-FB7E0517-229E-43A4-8448-04396D494D3F Q28705235-54975F87-4117-4C01-8D3F-E3500A087C1E Q29248111-3FF62BDF-DA48-46FB-BFAB-7F48A05D955B Q30510167-8D56CC1D-B4B5-4F67-B0BC-EB85D4C0F5F1 Q30525550-ABC64FBA-2033-4C5E-B603-B87C0967DE55 Q30544056-7B13AB81-C0FB-4FFC-87D7-9B67B3D1D5E9 Q30597182-DB217ED5-6DE7-4E0F-BFEB-5D0521C6D73D Q30659251-F0A8F9D6-CC2C-412C-86D9-7A26E9969EB6 Q31041660-46F40FD3-98C3-4647-AAFA-082434639D74 Q33666297-2E448363-CB68-48DC-8867-6C1B35FC1B5C Q33705614-7DD1F1B1-2310-44AF-9874-0C48FE4F1BF7 Q33797532-6825E9EE-16AF-4766-A15E-C37A8182AD42 Q33822641-E4187CC3-FA4D-4984-A96F-9CD4B28EBC43 Q33893280-C6CB8822-7FF0-4996-96F7-D76B21D0A680 Q34237637-4C897600-1913-468B-9041-6A831A5FCA35 Q34242682-D5B06CF1-4850-4636-B281-B89461C501A8 Q34295261-4A229DD9-18D5-463A-9E22-66480A1F9499 Q34337714-363B9372-016A-41D1-9F9F-B1FBC58E2433 Q34427734-C3BDB992-7E52-4282-9694-BB225240C744 Q34438204-70118806-07CF-4651-8C83-778699F8AACD Q34450431-5B52926D-866C-48AE-86B6-82C59A2C69EF Q34460662-09BCFEAA-8A9B-42B3-B726-E02AABBEF537

P2860

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

http://www.wikidata.org/entity/Q30501271

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

@ast

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

@en

type

label

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

@ast

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

@en

prefLabel

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

@ast

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

@en

P1433

Q30501271-7B1515A9-BD81-4005-90EE-E3CC3096B9C0

P1476

Q30501271-F4541802-252E-44AA-8C6F-916259D2CC36

P2093

Q30501271-02C08337-ED01-423A-9E86-98B1FCFA4121

Q30501271-062DB88A-9017-4F30-8536-1A027B5A1F14

Q30501271-171EA6C6-9B9C-4DB0-8393-C5328C213ABB

Q30501271-290B1FDE-5E3F-4D3E-BF51-ED0AF88DE425

Q30501271-2C386497-9908-48BC-AC7F-BB30AD1C12C7

Q30501271-37A2F252-86CE-4E20-A50D-A7F4EEA0150A

Q30501271-7939CBB8-D1DD-4B82-8D84-63B804410939

Q30501271-A1B1332A-72CA-40E4-8692-20E9BFE61FC2

Q30501271-A3C9DC67-3553-4AA8-B886-9F0B31521EB1

Q30501271-A44908D3-6349-4507-A42F-C36F86C6C1C5

P2860

Q30501271-08CECD0E-874A-4A72-91C0-BA67A4FAB0D2

Q30501271-0C4BD73D-85D1-4C97-A4BD-40D780EF1D4F

Q30501271-0D8E926F-DF83-42D6-9259-747F74D6A719

Q30501271-10E1B046-42D9-44AA-8541-A9402C5B5367

Q30501271-11D04472-EF0A-43FE-8CF9-45E4F35E7093

Q30501271-130B1126-0F3E-45A3-B8B3-9B92ACEAA0C6

Q30501271-1AE973DF-6AC5-46BA-A562-4D9E14F30AA9

Q30501271-25BFB640-AD4C-4B57-8B1C-8E5F5072E04B

Q30501271-26977739-5934-4AAF-8C3D-958CDC99DC04

Q30501271-2D363ED1-2BFA-4D16-9EC0-9E76264558D9

P304

Q30501271-44A3AF55-88F3-4940-8739-14A90B1AE8F6

P31

Q30501271-85B5B96C-6729-4BAC-B5F0-53AFE4E1950B

P356

Q30501271-ED6EE9CC-047D-450B-B8CA-C7A865D192A0

P433

Q30501271-1DE576C2-9C66-473C-BA5E-217496919A7B

P478

Q30501271-4C88AF31-B8A4-47AE-A480-D32B108FDD76

P50

Q30501271-23727709-1F5E-4C29-9A5F-BD798FB4421D

Q30501271-4D8BD9B3-C4DB-4B59-8EF9-EB9822B0CB6D

Q30501271-E0C3E15A-CDC7-4762-BF1E-7BA52420A1DB

P577

Q30501271-65DE7994-EDAC-4FEC-A798-842D56948BEB

P5875

Q30501271-4864E0F2-9B25-491D-85B9-0911808F7F7F

P698

Q30501271-1BD67F5F-F6C3-4F8E-B92D-EFD639FE7233

P921

Q30501271-0D2216B9-F88D-4516-B251-7FBD5BC98A03

Q30501271-71CBFFF6-9A96-4815-84F3-95881497A330

Q30501271-C8EB06B5-42CC-4199-967D-5E96238EB89F

P932

Q30501271-21F24CAA-5B72-4402-9B78-38AA08D0B862

P356

P1433

Annals of Neurology

P1476

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

@en

P2093

Aneeka M Hancock

http://www.w3.org/2001/XMLSchema#string

Carmen Ginghina

http://www.w3.org/2001/XMLSchema#string

David Goldstein

http://www.w3.org/2001/XMLSchema#string

Douglas Galasko

http://www.w3.org/2001/XMLSchema#string

Elaine R Peskind

http://www.w3.org/2001/XMLSchema#string

Hojoong M Kim

http://www.w3.org/2001/XMLSchema#string

James B Leverenz

http://www.w3.org/2001/XMLSchema#string

Jan Aasly

http://www.w3.org/2001/XMLSchema#string

Joshua Bradner

http://www.w3.org/2001/XMLSchema#string

Kathryn A Chung

http://www.w3.org/2001/XMLSchema#string

P2860

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease

FLT3: receptor and ligand

Control of microglial neurotoxicity by the fractalkine receptor

Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

P304

570-580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.22311

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Joseph Jankovic

P577

2011-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50378160

http://www.w3.org/2001/XMLSchema#string

P698

21400565

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

cerebrospinal fluid

P932

3117674

http://www.w3.org/2001/XMLSchema#string